Currently, some clinical trials have attempted to combine PD-(L)1/TGF-β bispecific antibodies and VEGF/VEGFR inhibitors in solid tumors, especially in difficult-to-treat tumors including BTC, pancreatic cancer and SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.